MRI combined with PET-CT of different tracers to improve the accuracy of glioma diagnosis: a systematic review and meta-analysis

Neurosurg Rev. 2019 Jun;42(2):185-195. doi: 10.1007/s10143-017-0906-0. Epub 2017 Sep 16.

Abstract

Based on studies focusing on positron emission tomography (PET)-computed tomography (CT) combined with magnetic resonance imaging (MRI) in the diagnosis of glioma, we conducted a systematic review and meta-analysis evaluating the pros and cons and the accuracy of different examinations. PubMed and Cochrane Library were searched. The search was conducted until April 2017. Two reviewers independently conducted the literature search according to the criteria set initially. Based on the exclusion criteria, 15 articles are included in this study. Of all studies that used MRI examination, there are five involving 18F-fluorodeoxyglucose-PET, five involving 11C-methionine-PET, five involving 18F-fluoro-ethyl-tyrosine-PET, and three involving 18F-fluorothymidine-PET. Due to the limitations such as lack of data, small sample size, and unrepresentative studies, we use a non-quantitative methodology. MRI examination can provide the anatomy information of glioma more clearly. PET-CT examinations based on tumor metabolism using different tracers have more advantages in determining the degree of glioma malignancy and boundaries. However, information provided by PET-CT of different tracers is not the same. With respect to the novel hybrid MRI/PET examination equipment proposed in recent years, the combination of MRI and PET-CT can definitively improve the diagnostic accuracy of glioma.

Keywords: Diagnostic accuracy; Glioma; MRI; PET-CT.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Brain Neoplasms / diagnostic imaging*
  • Glioma / diagnostic imaging*
  • Humans
  • Magnetic Resonance Imaging*
  • Positron Emission Tomography Computed Tomography*
  • Radiopharmaceuticals

Substances

  • Radiopharmaceuticals